Vertex Pharmaceuticals (VRTX): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Vertex Pharmaceuticals ( VRTX) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 1.0%. By the end of trading, Vertex Pharmaceuticals rose $1.86 (2.5%) to $76.53 on light volume. Throughout the day, 1,532,839 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 2,199,300 shares. The stock ranged in a price between $74.34-$76.59 after having opened the day at $74.67 as compared to the previous trading day's close of $74.67. Other companies within the Health Care sector that increased today were: GW Pharmaceuticals PLC ADR ( GWPH), up 75.8%, Opexa Therapeutics ( OPXA), up 17.0%, Cardiome Pharma Corporation ( CRME), up 16.4% and Receptos ( RCPT), up 14.2%.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Vertex Pharmaceuticals has a market cap of $17.4 billion and is part of the drugs industry. Shares are up 77.9% year to date as of the close of trading on Wednesday. Currently there are 12 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share.

On the negative front, Aratana Therapeutics ( PETX), down 17.7%, Venaxis ( APPY), down 10.7%, Transcept Pharmaceuticals ( TSPT), down 9.8% and Cell Therapeutics ( CTIC), down 6.4%.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

European and U.S. Stocks Called Higher as Earnings Season Hits Full-Speed

European and U.S. Stocks Called Higher as Earnings Season Hits Full-Speed

3 Things Investors Must Know for Monday

3 Things Investors Must Know for Monday

Street Stats: The Mid-Term Elections May Be a Rollercoaster Ride for Investors

Street Stats: The Mid-Term Elections May Be a Rollercoaster Ride for Investors

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC